BerGenBio ASA

BerGenBio ASA
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

Links

Bergenbio.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BerGenBio ASA: Invitation to First Quarter Presentation and Webcast

Wed, Apr 24, 2019 11:30 CET

Bergen, Norway, 24 April 2019 – BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio’s senior management team will take place at 10:00 am CET at: Felix Konferansesenter,Bryggetorget 3,0125 Oslo. The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished. The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

BerGenBio ASA: Invitation to First Quarter Presentation and Webcast

Subscribe

Media